CITRUS RESEARCH AND DEVELOPMENT FOUNDATION, INC.
Minutes of the
Commercial Product Delivery Committee Meeting
March 19, 2015

A meeting of the Commercial Product Delivery Committee of the Citrus Research and Development Foundation, Inc. was held on Thursday, March 19, 2015, at the University of Florida, IFAS, CREC, Ben Hill Griffin Hall, Lake Alfred, Florida. The meeting was properly noticed and recorded. The meeting was called to order at 9:30 am by Chairman Ben McLean. Roll was called and a quorum was present. Committee members participating were: Dr. Timothy L. Anglea; Mr. Larry Black; Mr. Joe L. Davis, Jr.; Dr. Mary L. Duryea (telephone); Mr. David Howard (telephone); Mr. Peter McClure (telephone); Mr. Ben McLean; Mr. Jerry Newlin; Mr. Andy Rackley; Ms. Shannon Shepp; Mr. Tom Stopyra; and Mr. Hugh Thompson. Mr. Ricke Kress did not participate. Also participating were: Dr. Harold Browning; Dr. Jim Dukowitz (telephone); Dr. Stephanie Slinski; Dr. Jim Syvertsen; and Dr. Tom Turpen.

Also in attendance were: Ms. Brandi Goller; Ms. LeAnna Himrod; Mr. Craig Noll; Ms. Audrey Nowicki; and Dr. Rosa Walsh.

Mr. Newlin moved to accept the minutes of the January 20, 2015 meeting. The motion was seconded by Mr. Stopyra. Mr. McLean asked for clarification of the reference to silver products having been tested; Dr. Turpen verified they have. The motion to accept the minutes passed unanimously.

Dr. Slinski further clarified that silver products from two sources were included in the L. crescens assays, and likely would be regulated as a new molecular entity.

Dr. Slinski gave an update on the NuFarm projects.

Dr. Slinski reported that AgroSource will present data collected through the third quarter of the projects during a closed Executive Committee meeting on March 24th, prior to the Board of Directors meeting. She and Dr. Browning attended a meeting with AgroSource and E.P.A. officials. CRDF and FFVA/TPR also had an informational meeting with the E.P.A. to discuss pathways for zinkicide registration for canker control.

Mr. Davis asked how the CRDF zinkicide project relates to the broader NIFA-funded project to continue the basic understanding of how the materials get into the plant as related to HLB. The CRDF funding is directed at getting products tested in the field and the regulatory process.

Dr. Dukowitz updated the committee on corporate relationships. Dr. Browning and Dr. Slinski attended a Florida Fruit and Vegetable Association meeting in January, leveraging leadership with companies, and providing contacts for further discussions on HLB solutions.

Dr. Syvertsen reviewed progress of the field trials, noting that the Duda & Sons tolerant rootstock site is being planted. The Ridge site at Peace River Packing Company is scheduled for planting around April 1st, and Ben Hill Griffin, Inc. site is scheduled for planting June/July 2015.

Mr. Black made a motion that Management Staff begin round two of tolerant rootstock trials with a similar model as Phase I. There was discussion about the CRDF evaluation team's ability to assist in collecting data from the UF St. Helena or Duda trials, making sure data are captured and the results are available to the industry. Seconded by Mr. Stopyra, the motion passed unanimously.
Dr. Browning reminded the committee that the data obtained from all CRDF-funded field trials is being provided for CRDF use. The rootstock varieties included in the current field trials have already been released to nurseries for grower use. While the UF and USDA breeding programs are conducting multiple trials throughout Florida, many do not collect data at the level planned for the CRDF trials. Mr. Black challenged staff to break down barriers with MTA in an attempt to obtain data-sharing on those trials.

Dr. Slinski presented a proposal for a field trial to evaluate the efficacy of five GRAS/biopesticide products as a preventative treatment and therapy for HLB on young Valencia orange trees, determining how effective the materials are in preventing CLas infection or reducing CLas titer in infected trees. Material costs are estimated to be $2,104 and crop consultant bids to date range from $19,200 to $79,000. Mr. Newlin moved to recommend the Board fund the GRAS/biopesticide field trial with crop consultant costs not to exceed $32,370, with the Management Team selecting the crop consultant. Seconded by Mr. Davis, the motion passed unanimously.

Dr. Browning started the discussion of the CPD projects terminating this fiscal year for the committee to recommend projects for continuation and submit a proposal. A number of projects were discussed clarifying objectives, volume of testing by the PCR labs, and the whether there is a need for ongoing funding.

Ms. Shepp offered that DOC labs and equipment at Lake Alfred could be utilized to keep up with demands for PCR and other testing, coordinating with Dr. Rosa Walsh.

Dr. Turpen clarified that the list provided with the meeting materials did not include Dr. Wang's project to control HLB using endophytic microbes from survivor trees.

Dr. Turpen reviewed one additional pre-proposal received from Dr. Santra to develop a zinc-based systemic antimicrobial for the prevention of citrus canker and HLB infection as an alternative to copper.

Mr. Stopyra made a motion for the generic support to approve the list of CPD projects that were discussed, inviting PI's to develop full plans and budgets for the projects with staff making recommendations where appropriate to the PI's. Seconded by Mr. Davis, the motion passed, with Mr. McLean abstaining due to a conflict of interest on the pre-proposal received from Dr. Ayyadurai on CytoSolve®, a project that was moved to the research category.

Mr. Thompson asked what the criteria are for moving projects from Research to CPD and suggested it should be reviewed annually to preserve the original function of the committee and remain focused on projects that can be moved into the marketplace with the balance managed elsewhere.

Dr. Turpen reported on the February 8th meeting of the nuPsyllid project participants. Since a front-runner of the three driver pathways has not been clearly identified, those teams as well as the effector and

outreach groups have been asked to provide updated objectives and budgets for the remaining half of the project to retain momentum towards meeting project objectives.

Dr. Browning reported the Knowledge Mapping group had a follow-up phone call. Dr. Susan Logue will make a presentation on the broader objectives to the Board, following up with additional details to be presented to the Research Management and Commercial Product Delivery committees next month identifying capacity building and structural needs. Topics being considered for Phase 2 of the Knowledge Mapping process include breeding resistance or psyllid intervention.

Mr. Davis asked for opinions on salicylic acid use and a discussion followed.

With no further business, the meeting was adjourned at 12:00 pm.

Minutes submitted by Audrey Nowicki